Non-Hodgkin Lymphoma Pipeline 2026: Latest FDA Approvals, Clinical Trials, And Emerging Therapies Assessment By Delveinsight Astrazeneca, Baxter, Bayer, Bristol Myers Squibb, Teva Pharma, Eli Lilly
“Non-Hodgkin Lymphoma Pipeline Insight, 2026 " report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Hodgkin Lymphoma Market.
The Non-Hodgkin Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Non-Hodgkin Lymphoma Pipeline Report:
Companies across the globe are diligently working toward developing novel Non-Hodgkin Lymphoma treatment therapies with a considerable amount of success over the years.
Non-Hodgkin Lymphoma companies working in the treatment market are Autolus, Genor Biopharma, AbbVie/ Genmab, AstraZeneca, Jiangsu Hengrui Medicine, Pacylex Pharmaceuticals, Zentera Therapeutics, TCR2 Therapeutics, Artiva Biotherapeutics, Loxo Oncology, Angiocrine Bioscience, AbbVie, Novartis, and others, are developing therapies for the Non-Hodgkin Lymphoma treatment
Emerging Non-Hodgkin Lymphoma therapies in the different phases of clinical trials are- AUTO4, GB226, Epcoritamab, Capivasertib, HRS-3738, PCLX-001, ZN-d5, TC-110, AB-101, LOXO-305, AB-205, Venetoclax, Tisagenlecleucel, and others are expected to have a significant impact on the Non-Hodgkin Lymphoma market in the coming years.
In June 2026, Ongoing global Phase II and Phase III studies continued evaluating next-generation CAR-T therapies, CD20-targeted bispecific antibodies, and combination regimens integrating immunotherapy with standard chemoimmunotherapy for DLBCL, follicular lymphoma, and mantle cell lymphoma. Investigators reported sustained response durability and favorable minimal residual disease (MRD) trends in interim analyses.
In May 2026, The U.S. FDA granted accelerated approval to BeOne Medicines' Beqalzi (sonrotoclax) for adults with relapsed or refractory Mantle Cell Lymphoma (MCL) after at least one prior therapy. Beqalzi became the first BCL-2 inhibitor approved specifically for MCL, based on clinical trial data demonstrating meaningful complete response rates in heavily pretreated patients. Mantle cell lymphoma is a subtype of Non-Hodgkin lymphoma.
In February 2026, Several companies continued enrollment and dose-expansion activities across Phase I/II studies investigating next-generation CD19- and CD20-directed CAR-T therapies, bispecific antibodies, and BCL-2 inhibitor combinations for relapsed or refractory B-cell Non-Hodgkin lymphoma, including DLBCL and follicular lymphoma. These studies focused on improving response durability while reducing cytokine release syndrome and neurotoxicity.
In January 2026, Incyte announced positive topline results from the Phase III frontMIND trial evaluating tafasitamab (Monjuvi) + lenalidomide + R-CHOP as first-line therapy for newly diagnosed high-risk Diffuse Large B-Cell Lymphoma (DLBCL). The study demonstrated a statistically significant improvement in progression-free survival (PFS) compared with R-CHOP alone, supporting plans for a regulatory submission to expand the therapy's indication.
In June 2025, Nurix Therapeutics shared encouraging clinical results from its ongoing NX-5948-301 Phase Ia/b trial, evaluating bexobrutideg (NX-5948) in patients with relapsed or refractory (R/R) B-cell malignancies.
In April 2025, Roche reported that the European Commission (EC) has granted approval for COLUMVI, in combination with gemcitabine and oxaliplatin (GemOx), for treating adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, who are unsuitable for autologous stem cell transplant (ASCT).
In February 2025, Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced the launch of waveLINE-010, a pivotal Phase 3 clinical trial. This study is evaluating the efficacy of zilovertamab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) versus the standard regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zilovertamab vedotin is Merck's investigational antibody-drug conjugate (ADC) designed to target receptor tyrosine kinase-like orphan receptor 1 (ROR1). The global recruitment for the waveLINE-010 trial is underway, and patient enrollment has begun.
In January 2025, The initial patient with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) has received a dose of SynKIR-310 in the Phase 1 CELESTIAL-301 trial (NCT06544265). This early-stage, multicenter study is designed to assess the safety, tolerability, and preliminary effectiveness of SynKIR-310 in individuals with R/R B-NHL, including subtypes such as diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma.
Non-Hodgkin Lymphoma Overview
Non-Hodgkin lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which is a part of the body's immune system. Unlike Hodgkin lymphoma, another type of lymphoma, Non-Hodgkin lymphoma does not typically involve the presence of Reed-Sternberg cells.
Get a Free Sample PDF Report to know more about Non-Hodgkin Lymphoma Pipeline Therapeutic Assessment-
Emerging Non-Hodgkin Lymphoma Drugs Under Different Phases of Clinical Development Include:
AUTO4: Autolus
GB226: Genor Biopharma
Epcoritamab: AbbVie/ Genmab
Capivasertib: AstraZeneca
HRS-3738: Jiangsu Hengrui Medicine
PCLX-001: Pacylex Pharmaceuticals
ZN-d5: Zentera Therapeutics
TC-110: TCR2 Therapeutics
AB-101: Artiva Biotherapeutics
LOXO-305: Loxo Oncology
AB-205: Angiocrine Bioscience
Venetoclax: AbbVie
Tisagenlecleucel: Novartis
Non-Hodgkin Lymphoma Pipeline Therapeutics Assessment
Non-Hodgkin Lymphoma Assessment by Product Type
Non-Hodgkin Lymphoma By Stage and Product Type
Non-Hodgkin Lymphoma Assessment by Route of Administration
Non-Hodgkin Lymphoma By Stage and Route of Administration
Non-Hodgkin Lymphoma Assessment by Molecule Type
Non-Hodgkin Lymphoma by Stage and Molecule Type
DelveInsight's Non-Hodgkin Lymphoma Report covers around 200+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Non-Hodgkin Lymphoma product details are provided in the report. Download the Non-Hodgkin Lymphoma pipeline report to learn more about the emerging Non-Hodgkin Lymphoma therapies
Some of the key companies in the Non-Hodgkin Lymphoma Therapeutics Market include:
Key companies developing therapies for Non-Hodgkin Lymphoma are - AstraZeneca, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Eli Lilly and Co., F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, and others.
Non-Hodgkin Lymphoma Pipeline Analysis:
The Non-Hodgkin Lymphoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin Lymphoma Treatment.
Non-Hodgkin Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin Lymphoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Non-Hodgkin Lymphoma drugs and therapies
Non-Hodgkin Lymphoma Pipeline Market Drivers
Increasing prevalence, ongoing and increased R&D activity, demand for innovative drugs and novel therapies are some of the important factors that are fueling the Non-Hodgkin Lymphoma Market.
Non-Hodgkin Lymphoma Pipeline Market Barriers
However, high cost of treatment, complications related to the drugs and other factors are creating obstacles in the Non-Hodgkin Lymphoma Market growth.
Scope of Non-Hodgkin Lymphoma Pipeline Drug Insight
Coverage: Global
Key Non-Hodgkin Lymphoma Companies: Autolus, Genor Biopharma, AbbVie/ Genmab, AstraZeneca, Jiangsu Hengrui Medicine, Pacylex Pharmaceuticals, Zentera Therapeutics, TCR2 Therapeutics, Artiva Biotherapeutics, Loxo Oncology, Angiocrine Bioscience, AbbVie, Novartis, and others
Key Non-Hodgkin Lymphoma Therapies: AUTO4, GB226, Epcoritamab, Capivasertib, HRS-3738, PCLX-001, ZN-d5, TC-110, AB-101, LOXO-305, AB-205, Venetoclax, Tisagenlecleucel, and others
Non-Hodgkin Lymphoma Therapeutic Assessment: Non-Hodgkin Lymphoma current marketed and Non-Hodgkin Lymphoma emerging therapies
Non-Hodgkin Lymphoma Market Dynamics: Non-Hodgkin Lymphoma market drivers and Non-Hodgkin Lymphoma market barriers
Request for Sample PDF Report for Non-Hodgkin Lymphoma Pipeline Assessment and clinical trials
Table of Contents
1. Non-Hodgkin Lymphoma Report Introduction
2. Non-Hodgkin Lymphoma Executive Summary
3. Non-Hodgkin Lymphoma Overview
4. Non-Hodgkin Lymphoma- Analytical Perspective In-depth Commercial Assessment
5. Non-Hodgkin Lymphoma Pipeline Therapeutics
6. Non-Hodgkin Lymphoma Late Stage Products (Phase II/III)
7. Non-Hodgkin Lymphoma Mid Stage Products (Phase II)
8. Non-Hodgkin Lymphoma Early Stage Products (Phase I)
9. Non-Hodgkin Lymphoma Preclinical Stage Products
10. Non-Hodgkin Lymphoma Therapeutics Assessment
11. Non-Hodgkin Lymphoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Non-Hodgkin Lymphoma Key Companies
14. Non-Hodgkin Lymphoma Key Products
15. Non-Hodgkin Lymphoma Unmet Needs
16. Non-Hodgkin Lymphoma Market Drivers and Barriers
17. Non-Hodgkin Lymphoma Future Perspectives and Conclusion
18. Non-Hodgkin Lymphoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment